Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.
Michael Choi, MD, discusses subsequent treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who progressed or experienced unacceptable intolerance with a prior covalent BTK inhibitor.
NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.